The past six weeks have not been kind to Onconova Therapeutics, as the chart above shows quite clearly. The company is expected to release top-line results from a phase III study of rigosertib in myelodysplastic syndrome (MDS) in December or the beginning of next year, so it's natural for investors to view the sharp sell off as a sign that negative data may have leaked.
Speculation about the possible failure of the rigosertib MDS study escalated further after Onconova posted a description of a new phase III study in MDS.
It's unlikely Onconova has bad rigostertib data in hand or planned the new study because it believes the current one will fail, so the only thing that's changed with the recent sell off is the risk/reward of being long the stock heading into the data announcement.
An objective look at the new rigosertib study should calm jangled nerves. The new study is designed to enroll only 90 MDS patients, compared to 270 patients in the ongoing study. The FDA and its counterparts in Europe aren't likely to approve a drug based on a study that is smaller than an older one that failed. If Onconova was planning a second pivotal study of rigosertib in MDS, it would more likely enroll a similar number of patients as the current study.
The new study is also described as a phase IIIb, which is different from a phase III study. A phase IIIb is meant to supplement regulatory submissions in an attempt to either expand a drug's label or obtain insurance reimbursement. This is the most likely reason for Onconova to conduct the new rigosertib study. The company noted on their most recent quarterly conference call that the new study is intended to provide patient access to rigosertib after completion of the phase III trial.
I still put the odds of a successful rigosertib phase III study in the high risk MDS population at around 60%. A close call but more likely to succeed than fail.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV